140 related articles for article (PubMed ID: 11262079)
1. Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
Jandu KS; Barrett V; Brockwell M; Cambridge D; Farrant DR; Foster C; Giles H; Glen RC; Hill AP; Hobbs H; Honey A; Martin GR; Salmon J; Smith D; Woollard P; Selwood DL
J Med Chem; 2001 Mar; 44(5):681-93. PubMed ID: 11262079
[TBL] [Abstract][Full Text] [Related]
2. 4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT(1B/1D) receptor agonist activity?
Knight YE; Edvinsson L; Goadsby PJ
Neuropharmacology; 2001 Mar; 40(4):520-5. PubMed ID: 11249961
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
[TBL] [Abstract][Full Text] [Related]
4. 4991W93, a potent blocker of neurogenic plasma protein extravasation, inhibits trigeminal neurons at 5-hydroxytryptamine (5-HT1B/1D) agonist doses.
Storer RJ; Akerman S; Connor HE; Goadsby PJ
Neuropharmacology; 2001 Jun; 40(7):911-7. PubMed ID: 11378161
[TBL] [Abstract][Full Text] [Related]
5. N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.
Xu YC; Johnson KW; Phebus LA; Cohen M; Nelson DL; Schenck K; Walker CD; Fritz JE; Kaldor SW; LeTourneau ME; Murff RE; Zgombick JM; Calligaro DO; Audia JE; Schaus JM
J Med Chem; 2001 Nov; 44(24):4031-4. PubMed ID: 11708905
[TBL] [Abstract][Full Text] [Related]
6. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
[TBL] [Abstract][Full Text] [Related]
7. 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
Chambers MS; Street LJ; Goodacre S; Hobbs SC; Hunt P; Jelley RA; Matassa VG; Reeve AJ; Sternfeld F; Beer MS; Stanton JA; Rathbone D; Watt AP; MacLeod AM
J Med Chem; 1999 Feb; 42(4):691-705. PubMed ID: 10052976
[TBL] [Abstract][Full Text] [Related]
8. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist.
Gupta P; Butler P; Shepperson NB; McHarg A
Eur J Pharmacol; 2000 Jun; 398(1):73-81. PubMed ID: 10856450
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of 5HT in migraine.
Buzzi MG
Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
[No Abstract] [Full Text] [Related]
10. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
[TBL] [Abstract][Full Text] [Related]
11. Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input.
Goadsby PJ; Classey JD
Neuroscience; 2003; 122(2):491-8. PubMed ID: 14614913
[TBL] [Abstract][Full Text] [Related]
12. 5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants.
Matzen L; van Amsterdam C; Rautenberg W; Greiner HE; Harting J; Seyfried CA; Böttcher H
J Med Chem; 2000 Mar; 43(6):1149-57. PubMed ID: 10737747
[TBL] [Abstract][Full Text] [Related]
13. Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans.
Classey JD; Bartsch T; Goadsby PJ
Brain Res; 2010 Nov; 1361():76-85. PubMed ID: 20833155
[TBL] [Abstract][Full Text] [Related]
14. 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
Russell MG; Matassa VG; Pengilley RR; van Niel MB; Sohal B; Watt AP; Hitzel L; Beer MS; Stanton JA; Broughton HB; Castro JL
J Med Chem; 1999 Dec; 42(24):4981-5001. PubMed ID: 10585208
[TBL] [Abstract][Full Text] [Related]
15. Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides.
Filla SA; Mathes BM; Johnson KW; Phebus LA; Cohen ML; Nelson DL; Zgombick JM; Erickson JA; Schenck KW; Wainscott DB; Branchek TA; Schaus JM
J Med Chem; 2003 Jul; 46(14):3060-71. PubMed ID: 12825944
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological activity of novel dimethyl-[2-[6-substituted-indol-1-yl]-ethyl]-amine as potent, selective, and orally-bioavailable 5-HT(1D) agonists.
Isaac M; Slassi M; Xin T; Arora J; O'Brien A; Edwards L; MacLean N; Wilson J; Demschyshyn L; Labrie P; Naismith A; Maddaford S; Papac D; Harrison S; Wang H; Draper S; Tehim A
Bioorg Med Chem Lett; 2003 Dec; 13(24):4409-13. PubMed ID: 14643336
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors.
Goadsby PJ; Knight Y
Br J Pharmacol; 1997 Nov; 122(5):918-22. PubMed ID: 9384509
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan.
Comer MB
Headache; 2002 Apr; 42 Suppl 2():S47-53. PubMed ID: 12028320
[TBL] [Abstract][Full Text] [Related]
19. The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
Petty MA; Elands J; Johnson MP; Linnik MD; Hamel E; Moskowitz MA; Lee WS; McCarty DR; Hibert M; Baron BM
Eur J Pharmacol; 1997 Oct; 336(2-3):127-36. PubMed ID: 9384224
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications.
Slassi A
Curr Top Med Chem; 2002 Jun; 2(6):559-74. PubMed ID: 12052194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
